Esteve Pharmaceuticals, S.A.
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Esteve Pharmaceuticals, S.A. sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Esteve Pharmaceuticals, S.A.: 2 sponsored US clinical trials, 1 recruiting.
Esteve Pharmaceuticals, S.A. sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is IGF1 Deficiency, with 1 trials.
Mid-pack sponsor footprint
Esteve Pharmaceuticals, S.A. is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
NCT00903110
Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.
NCT03108482
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Therapeutic Areas
Where Esteve Pharmaceuticals, S.A. enrollment is open (later-stage tilt)
1 recruiting of 2 indexed (50% open); 1 completed (50%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: IGF1 Deficiency (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Esteve Pharmaceuticals, S.A.: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Esteve Pharmaceuticals, S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Esteve Pharmaceuticals, S.A. page
2 registered trials is a research-attention snapshot, not an endorsement of Esteve Pharmaceuticals, S.A. or any single study.
- 1 of Esteve Pharmaceuticals, S.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- IGF1 Deficiency is the condition Esteve Pharmaceuticals, S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See IGF1 Deficiency trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Esteve Pharmaceuticals, S.A. pipeline card: 2 registered trials from official public datasets.Report a data error.